KSHV Modulation of Type I Interferon

I 型干扰素的 KSHV 调节

基本信息

项目摘要

DESCRIPTION (provided by applicant): Herpes infections represent one of the most common viral infections that exist in the world. These viruses can be subclinical or as in the case of Kaposi's Sarcoma Associated Herpesvirus (KSHV) they can lead to dangerous diseases such as cancer. KSHV is well known in AIDS patients to cause Kaposi's Sarcoma (KS) and several other lymphoproliferative diseases. These viruses setup infection in oral cavities and can be transmitted orally. The overall goal of this application is to define the interactions between KSHV and the innate immune response the virus elicits in infected cells in the oral cavity. We will focu on the innate immune response to KSHV infection, especially the Type I Interferon response. Type I Interferon is well known to be the body's natural anti-viral system and almost all viruses that cause infection in humans have devolved ways to block or use this system to enhance their replication in the host. The goal of this project is to lead to the development of novel, innate immune based therapeutics harnessing the power of the innate immune system to directly stop KSHV replication. We were the first group to determine how the innate immune system can recognize herpesviruses (including KSHV) and have also defined the signaling mechanisms that induce interferon (from the host side) and block interferon (from the virus side). This application is setup to determine how these systems interact together to lead to infection and disease. Long term work from this R03 grant will setup preliminary data to apply for a larger R01 grant that will explore how these mechanisms can be modulated to fight KSHV infection and associated diseases.
描述(由申请人提供):疱疹感染是世界上最常见的病毒感染之一。这些病毒可以是亚临床的,或者在卡波西肉瘤相关疱疹病毒(KSHV)的情况下,它们可以导致危险的疾病,如癌症。众所周知,KSHV在AIDS患者中引起卡波西肉瘤(KS)和其他几种淋巴组织增生性疾病。这些病毒在口腔中建立感染,并可经口传播。该应用程序的总体目标是定义KSHV之间的交互 而先天免疫反应是病毒在口腔中感染细胞中的释放。我们将重点关注KSHV感染的天然免疫反应,特别是I型干扰素反应。众所周知,I型干扰素是人体的天然抗病毒系统,几乎所有引起人类感染的病毒都有办法阻断或利用该系统来增强其在宿主中的复制。该项目的目标是开发新型的先天免疫疗法,利用先天免疫系统的力量直接阻止KSHV复制。我们是第一个确定先天免疫系统如何识别疱疹病毒(包括KSHV)的小组,也确定了诱导干扰素(从宿主侧)和阻断干扰素(从病毒侧)的信号传导机制。本申请 是为了确定这些系统如何相互作用,从而导致感染和疾病。长期的工作,从这个R03赠款将建立初步的数据,以申请一个更大的R01赠款, 探索如何调节这些机制来对抗KSHV感染和相关疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID JESSE SANCHEZ其他文献

DAVID JESSE SANCHEZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID JESSE SANCHEZ', 18)}}的其他基金

HIV Redirecting Innate Immunity by Vpu Targeting of JAK1
HIV 通过 Vpu 靶向 JAK1 重定向先天免疫
  • 批准号:
    10619889
  • 财政年份:
    2023
  • 资助金额:
    $ 10.95万
  • 项目类别:
Disruption of Type I Interferon Induction by a KSHV Homologue of IPS-1
IPS-1 的 KSHV 同系物对 I 型干扰素诱导的破坏
  • 批准号:
    10258718
  • 财政年份:
    2021
  • 资助金额:
    $ 10.95万
  • 项目类别:
KSHV Modulation of Type I Interferon
I 型干扰素的 KSHV 调节
  • 批准号:
    8542335
  • 财政年份:
    2013
  • 资助金额:
    $ 10.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了